If All You Have Is a Hammer …: Transplantation for Myelodysplastic Syndrome after Hypomethylating Agents Fail

In this month's issue, Festuccia et  al. describe how patients with myelodysplastic syndrome (MDS) fare when undergoing allogeneic hematopoietic cell transplantation (HCT) after hypomethylating agent (HMA) treatment, focusing on a comparison of those in whom HMA failed with those who responded to HMA [1]. The authors describe 125 pat ients with MDS at their institution who underwent HCT after HMA therapy between 2004 and 2013, representing the full spectrum of MDS, from refractory cytopenia with multilineage dysplasia to chronic myelomonocytic leukemia to refractory anemia with excess blasts 2.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research